What are the differential diagnoses for chronic urticarial rash associated with eosinophilia?

Differential Diagnoses for Chronic Urticarial Rash with Eosinophilia

When chronic urticaria presents with eosinophilia, you must systematically rule out parasitic infections first, followed by drug reactions, eosinophilic granulomatosis with polyangiitis (EGPA), hypereosinophilic syndrome (HES), allergic disorders, urticarial vasculitis, and autoinflammatory syndromes.

Primary Differential Diagnoses to Consider

1. Parasitic Infections (Most Common Globally)

• Strongyloidiasis is the most common parasitic cause, presenting with larva currens (rapidly moving linear urticarial rash on trunk/buttocks) 1
• Schistosomiasis causes urticaria during the migratory stage 1
• Other helminths: hookworm, ascariasis, visceral larva migrans
• Critical action: Obtain stool microscopy, serology for parasites, and consider empiric treatment if exposure history suggests infection 1

2. Drug Reactions

• Allergic drug eruptions are among the most common causes of secondary eosinophilia (80% of reactive cases) 2
• NSAIDs, antibiotics, and other medications can trigger both urticaria and eosinophilia
• Key distinguishing feature: Temporal relationship between drug exposure and symptom onset

3. Eosinophilic Granulomatosis with Polyangiitis (EGPA/Churg-Strauss)

• Classic triad: Asthma, eosinophilia, and systemic vasculitis 3
• Additional features: Sinus-nasal polyposis, peripheral neuropathy, cardiac involvement
• Laboratory findings: MPO-ANCA positive in 30-40% of cases 3
• Urticarial rash occurs but wheals typically last >24 hours and may leave residual pigmentation 4
• Critical tests: ANCA testing (MPO-ANCA), inflammatory markers (ESR, CRP), tissue biopsy showing eosinophilic vasculitis 3

4. Hypereosinophilic Syndrome (HES)

• Defined by persistent eosinophilia ≥1500 cells/µL with evidence of organ damage 2
• Organ involvement: Skin (urticaria, eczema), lungs, GI tract, heart (endomyocardial fibrosis), nervous system 2
• Myeloproliferative variant: Look for FIP1L1-PDGFRA fusion gene (responds to imatinib) 2
• Lymphocytic variant: Associated with T-cell clones producing IL-5
• Requires bone marrow examination and molecular testing for tyrosine kinase fusion genes 2

5. Allergic Disorders

• Allergic bronchopulmonary aspergillosis (ABPA): Asthma, pulmonary infiltrates, elevated IgE 2
• Food allergies: Can cause acute urticaria with eosinophilia 5
• Atopic dermatitis: May present with urticarial features and eosinophilia 2, 6

6. Urticarial Vasculitis

• Distinguishing features: Individual wheals last >24 hours, leave purpura/hyperpigmentation, associated with pain/burning rather than pure itch 4, 7
• May have systemic features: arthralgia, fever, elevated ESR
• Diagnosis requires: Skin biopsy showing leukocytoclastic vasculitis 7
• Check complement levels (C3, C4) - hypocomplementemic variant has worse prognosis 7

7. Autoinflammatory Syndromes

• Schnitzler syndrome: Chronic urticaria + monoclonal gammopathy (IgM) + fever + bone pain 8
• Cryopyrin-associated periodic syndromes: Urticaria + fever + systemic inflammation 9
• Elevated inflammatory markers (ESR, CRP) are characteristic 2

8. Bullous Pemphigoid (Urticarial Phase)

• Early pre-bullous stage can present as chronic urticaria with eosinophilia 8, 6
• Look for tense bullae development over time
• Diagnosis: Direct immunofluorescence showing linear IgG/C3 at basement membrane

9. Wells Syndrome (Eosinophilic Cellulitis)

• Recurrent episodes of edematous, urticarial plaques
• Histology shows "flame figures" (eosinophil degranulation around collagen) 8, 6

10. Hematologic Malignancies

• Lymphomas (especially T-cell, Hodgkin): Can present with urticaria and eosinophilia 2
• Systemic mastocytosis: Urticaria pigmentosa, flushing, elevated tryptase 4
• Advanced solid tumors rarely cause eosinophilia 2

Diagnostic Approach Algorithm

Step 1: Initial Assessment

• Complete blood count with differential (quantify eosinophilia: mild 1000-1499, moderate 1500-4999, severe ≥5000 cells/µL) 10
• Detailed medication history (including supplements, over-the-counter drugs)
• Travel and exposure history (parasites)
• Duration of individual wheals (<24 hours vs >24 hours) 7

Step 2: First-Line Investigations

• Stool microscopy ×3 and parasite serology (if any exposure risk) 1
• ESR and CRP (elevated suggests vasculitis or autoinflammatory disease) 7
• Total IgE level
• ANCA testing (MPO-ANCA for EGPA) 3
• Serum tryptase (if mastocytosis suspected) 4

Step 3: If Wheals Last >24 Hours

• Skin biopsy of lesional skin to rule out urticarial vasculitis 7
• Complement levels (C3, C4) 7

Step 4: If Systemic Features Present

• Chest X-ray or CT (pulmonary infiltrates suggest EGPA, ABPA, eosinophilic pneumonia)
• Echocardiogram (cardiac involvement in HES, EGPA) 2
• Nerve conduction studies (if neuropathy suspected in EGPA)
• Serum protein electrophoresis (Schnitzler syndrome) 8

Step 5: If Eosinophilia Severe (≥5000) or Organ Damage

• Bone marrow examination with cytogenetics 2
• Molecular testing for FIP1L1-PDGFRA, PDGFRB, FGFR1 fusion genes 2
• Organ-specific evaluation based on symptoms 2

Step 6: Consider Specialist Referral

• Allergist-immunologist for chronic urticaria evaluation, autoimmune workup, and physical urticaria testing 4
• Hematology if clonal eosinophilia or HES suspected 2
• Rheumatology if EGPA or systemic vasculitis suspected 3

Critical Pitfalls to Avoid

1. Don't assume all chronic urticaria with eosinophilia is "just allergic" - parasites and systemic diseases must be excluded 2, 1

2. Don't order extensive laboratory panels indiscriminately - most chronic ordinary urticaria doesn't require extensive testing 7. Let clinical features guide investigation.

3. Don't miss EGPA - the combination of asthma, eosinophilia, and urticaria should trigger ANCA testing and consideration of systemic vasculitis 3

4. Don't overlook drug causes - carefully review ALL medications including recent additions or changes 2

5. Don't forget to assess wheal duration - wheals lasting >24 hours mandate skin biopsy to exclude urticarial vasculitis 4, 7

6. Don't delay parasite evaluation in endemic areas or with travel history - empiric treatment may be warranted while awaiting results 1

7. In severe eosinophilia (≥5000), don't delay hematology referral - myeloproliferative HES with FIP1L1-PDGFRA responds dramatically to imatinib and delays can lead to irreversible organ damage 2